Volume 33, No 7, Jul 2023
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 33 Issue 7, July 2023: 491-492
Precision medicine for metastatic TNBC: the FUTURE is now
Julia Foldi1 , Charles E. Geyer Jr1,2,*1Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Despite well-described molecular heterogeneity of triple negative breast cancer (TNBC), management of metastatic disease primarily relies on cytotoxic chemotherapies, in some cases combined with immunotherapy, without consideration of molecular subtypes. In a recent Cell Research article, Liu et al. show the feasibility and promise of a precision medicine-guided treatment approach for heavily pretreated metastatic TNBC.